115175-19-4

Basic information

• Product Name: 3-AMINO-N-(4-METHOXYPHENYL)BENZAMIDE
• Synonyms: 3-AMINO-N-(4-METHOXYPHENYL)BENZAMIDE;OTAVA-BB 994993;UKRORGSYN-BB BBV-033064;3-amino-N-(4-methoxyphenyl)benzamide(SALTDATA: FREE);Benzamide, 3-amino-N-(4-methoxyphenyl)-
• CAS NO: 115175-19-4
• Molecular Formula: C₁₄H₁₄N₂O₂
• Molecular Weight: 242.28
• Mol File: 115175-19-4.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 362.8°C at 760 mmHg
• Flash Point: 173.2°C
• Appearance: /
• Density: 1.245g/cm³
• Vapor Pressure: 1.89E-05mmHg at 25°C
• Refractive Index: 1.658
• CAS DataBase Reference: 3-AMINO-N-(4-METHOXYPHENYL)BENZAMIDE(CAS DataBase Reference)
• NIST Chemistry Reference: 3-AMINO-N-(4-METHOXYPHENYL)BENZAMIDE(115175-19-4)
• EPA Substance Registry System: 3-AMINO-N-(4-METHOXYPHENYL)BENZAMIDE(115175-19-4)

Safety Data

• Hazard Codes: Xi
• HazardClass: IRRITANT
• Hazardous Substances Data: 115175-19-4(Hazardous Substances Data)

Usage

General Description

3-AMINO-N-(4-METHOXYPHENYL)BENZAMIDE is a chemical compound with the molecular formula C14H14N2O2. It is an organic compound that contains an amino group and a benzamide group, with a methoxyphenyl group attached to the nitrogen atom. This chemical is commonly used in pharmaceutical research and drug development. It may have potential applications in the treatment of various medical conditions, and its synthesis and properties are of interest to scientists and researchers in the field of medicinal chemistry. Further research and testing may be necessary to fully understand the potential uses and effects of this compound.

InChI:InChI=1/C14H14N2O2/c1-18-13-7-5-12(6-8-13)16-14(17)10-3-2-4-11(15)9-10/h2-9H,15H2,1H3,(H,16,17)

Upstream product

• 101971-72-6 N-(4'-methoxyphenyl)-3-nitrobenzamide 
• 104-94-9 4-methoxy-aniline 
• 121-90-4 m-nitrobenzoic acid chloride 
• 121-92-6 3-nitrobenzoic acid 

Downstream Products

• 1233188-82-3 3-(2-chloro-acetylamino)-N-(4-methoxy-phenyl)-benzamide 
• 1001426-54-5 C₁₇H₁₇BrN₂O₃ 
• 90233-65-1 C₁₆H₁₉N₃O₄S 

Relevant articles and documents

Synthesis and in Vitro and in Vivo anticoagulant and antiplatelet activities of amidino- and non-amidinobenzamides

Three amidino- and ten non-amidinobenzamides were synthesized as 3-aminobenzoic acid scaffold-based anticoagulant and antiplatelet compounds. The anticoagulant activities of thirteen synthesized compounds 1-13, and 2b and 3b as prodrugs were preliminary evaluated by screening the prolongation of activated partial thromboplastin time (aPTT) and prothrombin time (PT) in vitro. From the aPTT results obtained, two amidinobenzamides, N-(3′-amidinophenyl)-3-(thiophen-2″-ylcarbonylamino) benzamide (1, 33.2 ± 0.7 s) and N-(4′-amidinophenyl)-3-(thiophen-2″-ylcarbonylamino) benzamide (2, 43.5 ± 0.6 s) were selected to investigate the further anticoagulant and antiplatelet activities. The aPTT results of 1 (33.2± 0.7 s) and 2 (43.5 ± 0.6 s) were compared with heparin (62.5 ± 0.8 s) in vitro at 30 μM. We investigated the effect of 1 and 2 on blood anticoagulant activity (ex vivo) and on tail bleeding time (in vivo) on mice. A tail cutting/bleeding time assay revealed that both 1 and 2 prolonged bleeding time in mice at a dose of 24.1 g/mouse and above. Compounds 1 and 2 dose-dependently inhibited thrombin-catalyzed fibrin polymerization and platelet aggregation. In addition, 1 and 2 were evaluated on the inhibitory activities of thrombin and FXa as well as the generation of thrombin and FXa in human umbilical vein endothelial cells (HUVECs). Collectively, 1 and 2 possess some antiplatelet and anticoagulant activities and offer a basis for development of a novel antithrombotic product.

A GROUP OF AMINO SUBSTITUTED BENZOYL DERIVATIVES AND THEIR PREPARATION AND THEIR USE

A group of amino substituted benzoyl derivatives, their preparation and their use. The screening and research on an antiviral drug with hA3G/Vif as a target point proves that the 3-amino benzoyl derivatives not only have the combined activity for the hA3G/Vif, but also have a function of inhibiting replication of viruses. The present invention provides the possible breakthrough progress for the problem of HIV drug resistance, thereby providing a novel clinical antiviral drug which has higher efficiency.

3-(2′-Bromopropionylamino)-benzamides as novel S-phase arrest agents

We report the synthesis, antiproliferative activity, and SAR of novel 3-(2′-bromopropionylamino)-benzamides. Many of the benzamide compounds showed potent cytotoxicities against Molt-3 leukemia cells. Several compounds exihibited cytotoxicities (under 6.5